REG - GSK PLC - RSV older adult vaccine submission in Japan

GSKAnnouncement

21/10/2022 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221021:nRSU6400Da&default-theme=true

RNS Number : 6400D  GSK PLC  21 October 2022

Issued: 21 October 2022, London UK

 

GSK regulatory submission accepted by Japanese regulator for respiratory
syncytial virus older adult vaccine candidate

 

·   Regulatory submission based on positive pivotal phase III data showing
vaccine efficacy against respiratory syncytial virus-lower respiratory tract
disease in adults aged 60 years and above with a favourable safety profile

·   Further announcements on regulatory progress in the US and EU are
expected in Q4 2022

 

GSK plc (LSE/NYSE: GSK) today announced that a new drug application for its
respiratory syncytial virus (RSV) older adult vaccine candidate has been
accepted for review by the Japanese Ministry of Health, Labour and Welfare
(MHLW). The proposed indication is for adults aged 60 years and above to
prevent lower respiratory tract diseases (LRTD) caused by RSV.

 

The filing is based on positive data from a prespecified interim analysis of
the pivotal AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial
which showed high overall vaccine efficacy against RSV-LRTD in adults aged 60
years and above, with a favourable safety profile. Consistent high vaccine
efficacy was observed against LRTD in severe disease, adults aged 70-79 years,
adults with underlying comorbidities and across RSV A and B strains.

 

Further announcements on regulatory progress in the US and EU are anticipated
before the end of 2022. GSK's RSV older adult vaccine candidate contains a
recombinant subunit prefusion RSV F glycoprotein antigen (RSVPreF3) combined
with GSK's proprietary AS01(E) adjuvant. There are currently no RSV vaccines
for adults approved anywhere in the world.

 

About the AReSVi-006 trial

The AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial is a
randomised, placebo-controlled, observer-blind, multi-country trial to
demonstrate the efficacy of a single dose of GSK's adjuvanted RSVPreF3 OA
investigational vaccine in adults aged 60 years and above. Approximately
25,000 participants were enrolled from 17 countries.

 

About respiratory syncytial virus (RSV) in adults

RSV is a common contagious virus affecting the lungs and breathing passages.
It is one of the major remaining infectious diseases for which there is
currently no vaccine or specific treatment available for adults. Older adults
are at high risk for severe disease due to age-related decline in immunity and
underlying conditions. RSV can exacerbate conditions, including chronic
obstructive pulmonary disease (COPD), asthma and chronic heart failure and can
lead to severe outcomes, such as pneumonia, hospitalisation, and death. Each
year, RSV causes over 420,000 hospitalisations and 29,000 deaths in adults in
industrialised countries, including approximately 57,000 and 4,000,
respectively in Japan. Adults with underlying conditions are more likely to
seek medical advice and have higher hospitalisation rates than adults without
these conditions.

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com/company
(https://www.gsk.com/en-gb/about-us/)

 

 GSK enquiries
 Media:               Tim Foley         +44 (0) 20 8047 5502  (London)
                      Simon Moore       +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn    +1 202 603 5003       (Washington DC)
                      Lyndsay Meyer     +1 202 302 4595       (Washington DC)

 Investor Relations:  Nick Stone        +44 (0) 7717 618834   (London)
                      James Dodwell     +44 (0) 20 8047 2406  (London)
                      Mick Readey       +44 (0) 7990 339653   (London)
                      Josh Williams     +44 (0) 7385 415719   (London)
                      Jeff McLaughlin   +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco  +1 215 751 4855       (Philadelphia)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described in
the Company's Annual Report on Form 20-F for 2021, GSK's Q2 Results for 2022
and any impacts of the COVID-19 pandemic.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCMMBTTMTMTTMT